Infliximab in the treatment of Crohn's disease: A user's guide for clinicians

Keyphrases

• Acetaminophen 20%
• Active Infection 20%
• Acute Infusion Reaction 20%
• Antibody Formation 20%
• Antinuclear Antibodies 20%
• Azathioprine/6-mercaptopurine 20%
• Chimeric Antibody 20%
• Clinical Presentation 20%
• Conventional Therapy 40%
• Corticosteroids 20%
• Crohn's Disease 100%
• Delayed Hypersensitivity 40%
• Diphenhydramine 20%
• Dose Rate 20%
• Dosing Strategy 20%
• Early Use 20%
• Enterocutaneous Fistula 20%
• Extraintestinal Manifestations 20%
• Fistula 80%
• Hospitalized Patients 20%
• Immunosuppressive Therapy 20%
• Improved Outcomes 20%
• Induction Regimen 20%
• Induction Therapy 20%
• Infliximab 100%
• Infliximab Therapy 40%
• Infusion Reaction 20%
• Lack of Response 20%
• Maintenance Dose 20%
• Maintenance of Remission 20%
• Methotrexate 20%
• Onset of Action 20%
• Optimal Dosing 20%
• Patients at Risk 20%
• Perianal Crohn's Disease 40%
• Perianal Fistula 20%
• Rapid Onset 20%
• Remission 20%
• Remission Induction 20%
• Retreatment 20%
• Risk Reduction 20%
• Steroid-sparing 20%
• Tuberculosis 20%
• User Guide 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Antinuclear Antibody 14%
• Anus Fistula 14%
• Azathioprine 14%
• Chimeric Antibody 14%
• Combination Therapy 14%
• Crohn's Disease 100%
• Delayed Hypersensitivity 28%
• Diphenhydramine 14%
• Enterocutaneous Fistula 14%
• Fistula 57%
• Immunosuppressive Agent 14%
• Infection 28%
• Infliximab 100%
• Mercaptopurine 14%
• Methotrexate 14%
• Paracetamol 14%
• Physical Disease by Body Function 14%
• Remission 28%